Advertisement

Initial Liberation of Biogenic Amines and Effect of Further Mediators Following Application of Endotoxins

  • A. Schauer

Abstract

In shock sensitive species shock symptoms develop very quickly after the application of endotoxins. This phenomenon has led to extensive comparisons of anaphylactic and endotoxin shocks (4). The anaphylactic shock clearly results from a massive liberation of histamine from tissue mast cells. According to Becker and Austen (3) this takes place under the influence of so-called homocytotropic antibodies after sensibilization of the mast cells, as shown in experiments with rats. In contrast to this relatively simple mechanism, the factors leading to endotoxin shock are many-faceted and much more complex.

Keywords

Mast Cell Biogenic Amine Anaphylactic Shock Histamine Level Kinin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aures, D., Hakanson, R., Schauer, A.: Europ. J. Pharmacol. 3: 217 (1968).CrossRefGoogle Scholar
  2. 2.
    Aures, D., Clark, W.G.: Ann. Biochem. 9: 35 (1964).CrossRefGoogle Scholar
  3. 3.
    Becker, E. L., Austen, K. F.: J. exp. Med. 124: 379 (1966).PubMedCrossRefGoogle Scholar
  4. 4.
    Braude, A. I.: Absorption, distribution, and elimination of endotoxins and their derivations. In: Landy, M., Braun, W.: Bacterial Endotoxins, p. 98 ( Rutgers Univ. Press, New Brunswick, N. J. 1964 ).Google Scholar
  5. 5.
    Carretero, O.A., Nasjletti, A., Fasciolo, J. C.: Experientia 26: 63 (1970).PubMedCrossRefGoogle Scholar
  6. 6.
    Cline, M. J., Melmon, K. L., Davis, W. C., Williams, H. E.: Brit. J. Haemat. 15: 539 (1968).PubMedCrossRefGoogle Scholar
  7. 7.
    Diniz, C. R., Carvalho, I. F., Reis, M. L., Corrado, A. P.: 3rd Int. Congr. on vasoactive polypeptides, editor Rocha e Silva, Sao Paulo 1967.Google Scholar
  8. 8.
    Erdös, E. G., Miwa, I.: Fed. Proc. 27: 92 (1968).PubMedGoogle Scholar
  9. 9.
    Habermann, E.: Neue Aspekte der Trasyloltherapie,vol. 3, p. 35 ( Schattauer, Stuttgart 1969 ).Google Scholar
  10. 10.
    Hinshaw, L. B., Jordan, M. M., Vick, J. A.: J. clin. Invest. 40: 1631 (1961).PubMedCrossRefGoogle Scholar
  11. 11.
    Kimball, H. R., Melmon, K. L., Wolff, S. M.: Proc. Soc. exp. Biol. Med. 139: 1078 (1972).PubMedGoogle Scholar
  12. 12.
    Kobold, E. E., Lovell, R., Katz, W., Thal, A. P.: Surg. Gynec. Obstet. 118: 807 (1964).PubMedGoogle Scholar
  13. 13.
    Massion, W. H., Erdös, E. G.: J. Oklahoma State Med. Ass. 59: 467 (1966).Google Scholar
  14. 14.
    Meyer, A., Werle, E.: Europ. Pancreas Symp., Erlangen 1963 ( Schattauer, Stuttgart 1964 ).Google Scholar
  15. 15.
    Nies, A. S., Forsyth, R. P., Williams, H. E., Melmon, K. L.: Circulation Res. 22: 155 (1968).PubMedGoogle Scholar
  16. 16.
    Nowotny, A.: Naturwissenschaften 58: 397 (1971).PubMedCrossRefGoogle Scholar
  17. 17.
    Raskova, H., Vanecek, J.: Pharmacol, Rev. 16: 1 (1964).Google Scholar
  18. 18.
    Rothschild, A. M., Castania, A.: J. Pharm. Pharmacol. 20: 77 (1968).PubMedCrossRefGoogle Scholar
  19. 19.
    Scharnagel, K., Greef, K., Luehn, R., Strohbach, H.: Arch. exp. Path. Pharmakol. 250: 176 (1965).CrossRefGoogle Scholar
  20. 20.
    Schauer, A., Menzinger, I., Gielow, L.: Nature 212: 1249 (1966).PubMedCrossRefGoogle Scholar
  21. 21.
    Schauer, A., Gielow, L., Calvoer, R.: Kiln. Wschr. 45: 593 (1967).CrossRefGoogle Scholar
  22. 22.
    Schauer, A., Gielow, L.: Verh. dtsch. Ges. Path. 51: 271 (1967).Google Scholar
  23. 23.
    Schayer, R. W.: Science 131: 226 (1960).PubMedCrossRefGoogle Scholar
  24. 24.
    Schayer, R. W., Rothschild, Z., Bizony, P.: Amer. J. Physiol. 196: 295 (1959).PubMedGoogle Scholar
  25. 25.
    Shah, J. P., Shah, U. S., Appert, H. E., Howard, J. M.: J. Trauma 10: 255 (1970).PubMedCrossRefGoogle Scholar
  26. 26.
    Shore, O. A., Burkhalter, A., Cohn, V. H.: J. Pharmacol. exp. Ther. 122: 182 (1959).Google Scholar
  27. 27.
    Spink, W. W., Davis, R. B., Potter, R., Chartrand, S.: J. clin. Invest. 43: 696 (1964).PubMedCrossRefGoogle Scholar
  28. 28.
    Urbaschek, B., Kotowski, H., Bäurle, H.: Z. ImmunForsch. 122: 343 (1961).Google Scholar
  29. 29.
    Urbaschek, B., Versteyl, R.: Nature 207: 763 (1965).PubMedCrossRefGoogle Scholar
  30. 30.
    Urbaschek, B., Versteyl, R., Götte, D.: Kiin. Wschr. 43: 1012 (1965).CrossRefGoogle Scholar
  31. 31.
    Urbaschek, B., Huth, K., Krecke, H. J.: Endotoxin nduced microcirculatory disturbances and interaction to various metabolic parameters including the coagulation system. Bibl. anat., vol. 10, p. 442 ( Karger, Basel/New York 1969 ).Google Scholar
  32. 32.
    Vick, J. A., Hinshaw, L. B., Carlson, C. H., Fan, Y. L.: Proc. Soc. exp. Biol. Med. 104: 379 (1960).PubMedGoogle Scholar
  33. 33.
    Vick, J.A., Mehlman, Heiffer, M.H.: Proc. Soc. exp. Biol. Med. 137: 902 (1971).PubMedGoogle Scholar
  34. 34.
    Webster, M. E., Clark, W. R.: Amer. J. Physiol. 197: 406 (1959).PubMedGoogle Scholar
  35. 35.
    Weil, M. H., Spink, W. W.: J. Lab. clin. Med. 50: 501 (1957).PubMedGoogle Scholar
  36. 36.
    Werle, E., Amann, R.: Klin. Wschr. 34: 624 (1956).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1975

Authors and Affiliations

  • A. Schauer

There are no affiliations available

Personalised recommendations